Инфекции нижних дыхательных путей при ревматических заболеваниях
https://doi.org/10.14412/1996-7012-2018-1-47-54
Аннотация
Инфекции нижних дыхательных путей занимают ведущее место у больных ревматическими заболеваниями (РЗ). Наиболее частым возбудителем пневмоний (Пн) как в общей популяции, так и при РЗ остается пневмококк (S. pneumoniae). В настоящем обзоре приведены частота и факторы риска Пн при различных РЗ. Представлены основные клинические характеристики, подходы к терапии и профилактике Пн, обусловленных различными (в том числе оппортунистическими) инфекциями. Проблема Пн у больных с РЗ весьма актуальна и одновременно крайне мало разработана – в отечественной литературе ей посвящены единичные публикации. Необходимы дальнейшие исследования ее различных аспектов (включая эффективность и безопасность вакцинации) на территории России в рамках единой научной программы, что позволит создать клинические рекомендации по ведению таких пациентов.
Об авторах
Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Д. В. Буханова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Заболеваемость всего населения России в 2016 году. Статистические материалы. Часть I. Москва; 2017. [Zabolevaemost' vsego naseleniya Rossii v 2016 godu. Statisticheskie materialy. Chast' I [The morbidity of Russia's population in 2016. Statistical data. Part I]. Moscow; 2017.].
2. Зайцев АА. Внебольничная пневмония: «bene dignoscitur, bene curator». Consilium Medicum. 2017;(3):55-60. [Zaitsev AA. Community-acquired pneumonia: «bene dignoscitur, bene curator». Consilium Medicum. 2017;(3):55-60. (In Russ.)].
3. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007 Jul;46(7):1157-60. doi.org/10.1093/rheumatology/kem076.
4. Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.
5. Mori S, Yoshitama T, Hidaka T, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One. 2017;12(6): e0179179. doi: 10.1371/journal.pone.0179179
6. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008 Mar;35(3):387-9.
7. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012 Dec; 66(12):1177-81. doi: 10.1136/jech-2011-200168
8. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al.Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006 Jul-Aug; 35(4):273-6. doi: 10.1080/03009740600556258
9. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481-94.
10. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205. doi: 10.1136/ard.2010.148700
11. Yoo HG, Yu HM, Jun JB, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol. 2013 Jul;23(4):709-15. doi: 10.1007/s10165-012-0716-8
12. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 Feb;54(2): 628-34. doi: 10.1002/art.21568
13. Полянская МВ. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска. Автореф. дисс. канд. мед. наук. Москва; 2009. 24 с. [Polyanskaya MV. Pneumonia in patients with rheumatic diseases: incidence, clinical presentation, risk factors. Avtoref. diss. kand. med. nauk. Moscow; 2009. 24 p.]
14. Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol. 2007;34(9):1832-6.
15. Zamora-Legoff JA, Krause ML, Crowson CS, Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2016;35(10):2585- 9. doi: 10.1007/s10067-016-3357-z
16. Takayanagi N. Biological agents and respiratory infections: Causative mechanisms and practice management. Respir Investig. 2015 Sep;53(5):185-200. doi: 10.1016/j.resinv.2015.03.003
17. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-12. doi: 10.1002/art.21386
18. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007 Feb;46(2):327-34. doi:10.1093/rheumatology/kel236
19. Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137(12):533-40. doi: 10.1016/j.medcli.2010.11.032
20. Lane MA, McDonald JR, Zeringue AL, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore). 2011;90(2):139-45. doi: 10.1097/MD.0b013e318211106a.
21. Van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956
22. Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012;22(1):122-7. doi: 10.1007/s10165-011-0488-6
23. Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66(3):308-12. doi: 10.1002/art.22430
24. Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health. 2007;38(3):528-36.
25. Kinder BW, Freemer MM, King TE Jr, et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007;56(8):2679-86. doi: 10.1002/art.22804
26. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11): 1897-905. doi: 10.1136/annrheumdis-2017-211448.
27. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522
28. Poormoghim H, Moradi Lakeh M, Mohammadipour M, et al. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int. 2012;32(8):2431-44. doi: 10.1007/s00296-011-1967-y.
29. Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One. 2015 May 1;10(5):e0124205. doi: 10.1371/journal.pone.0124205.
30. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036-43. doi: 10.1136/ard.2009.109389
31. McGregor JG, Negrete-Lopez R, Poulton CJ, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i171-81. doi: 10.1093/ndt/gfv045.
32. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006 Nov 15;43(10):e95-100. doi: 10.1086/508538
33. Bodro M, Carratalа J, Paterson DL. Legionellosis and biologic therapies. Respir Med. 2014 Aug;108(8):1223-8. doi: 10.1016/j.rmed.2014.04.017.
34. Di Franco M, Lucchino B, Spaziante M, et al. Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections. Int J Mol Sci. 2017 Jan 29;18(2). pii: E293. doi: 10.3390/ijms18020293.
35. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012 Dec;51(12): 2120-30. doi: 10.1093/rheumatology/kes244
36. Wissmann G, Morilla R, Martin-Garrido I, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest. 2011;41(3):343-8. doi: 10.1111/j.1365-2362.2010.02415.x
37. Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford). 2011;50(3): 569-77. doi: 10.1093/rheumatology/keq314
38. Fritzsche C, Riebold D, Munk-Hartig A, et al. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol. 2012;41(3):208-13. doi: 10.3109/03009742.2011.630328
39. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780-9.
40. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken). 2010; 62(11):1661-4. doi: 10.1002/acr.20279
41. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 2008;47(8): 1256-7. doi: 10.1093/rheumatology/ken234
42. Tsai MJ, Chou CW, Lin FC, Chang SC. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus. 2012;21(8):914-8. doi: 10.1177/0961203312436855
43. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34(8):1098-107.
44. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust. 1995;162(5):233-5.
45. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010;37(4):686-8. doi: 10.3899/jrheum.091426
46. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for themanagement of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583-94. doi: 10.1136/annrheumdis-2016-209133
47. Wolfe RM, Peacock JE. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? Curr Rheumatol Rep. 2017 Jun;19(6):35. doi: 10.1007/s11926-017-0664-6
48. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004; 4:42. doi:10.1186/1471-2334-4-42.
49. Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014 Dec;34(12): 1765-71. doi: 10.1007/s00296-014-3073-4.
50. Demoruelle MK, Kahr A, Verilhac K, et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res. 2013;65(2):314-23. doi: 10.1002/acr.21857.
51. Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-28.
52. Olson TC, Bongartz T, Crowson CS, et al Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009. BMC Infect Dis. 2011 May 23;11:145. doi: 10.1186/1471-2334-11-145.
53. Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor- α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015; 61(3): 409-17. doi: 10.1093/cid/civ299
54. Taroumian S, Knowles SL, Lisse JR et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1903-9. doi: 10.1002/acr.21784.
55. Ren LM, Li Y, Zhang CF, et al. Clinical characteristics and associated risk factors of cytomegalovirus infection in patients with underlying systemic Rheumatic diseases. Zhonghua Yi Xue Za Zhi. 2016 Sep 20;96(35):2772-6.
56. Bengtsson C, Kapetanovic MC, Kä llberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010;69(10):1831-3. doi: 10.1136/ard.2010.129908
57. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011; 70(3):414-22. doi: 10.1136/ard.2010.137216
58. Bluett J, Jani M, Symmons DP. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2017 Dec;4(2):309-32. doi: 10.1007/s40744-017-0071-5
59. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol. 2009;21(4):419-24. doi: 10.1097/BOR.0b013e328329ec6e.
60. Sergeeva MS, Belov BS, Tarasova GM, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine for patients with rheumatoid arthritis: results from 2-year follow up. Ann Rheum Dis. 2017;76 (Suppl 2): 251. doi: 10.1136/annrheumdis-2017-eular.2070
61. Tarasova GM, Belov BS, Sergeeva MS, et al. Tolerability, efficacy and immunogenicity of 23-valent pneumococcal vaccine in sle patients. Ann Rheum Dis. 2017;76 (Suppl 2): 1226. doi: 10.1136/annrheumdis-2017-eular.2347.
62. Буханова ДВ, Белов БС, Тарасова ГМ, и др. Оценка безопасности и эффективности противогриппозной вакцинации у больных ревматическими заболеваниями (предварительные результаты).II Междисциплинарная конференция «Аутоиммунные и иммунодефицитные заболевания». Научно-практическая ревматология. 2017;55(Приложение 2):8-9. [Bukhanova DV, Belov BS, Tarasova GM, et al. Safety assessment and effectiveness of influenza vaccination in patients with rheumatic diseases (preliminary data). Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(Suppl 2):8-9. (In Russ.)]. doi: 10.14412/1995-4484-2017- 4-28
Рецензия
Для цитирования:
Белов Б.С., Буханова Д.В., Тарасова Г.М. Инфекции нижних дыхательных путей при ревматических заболеваниях. Современная ревматология. 2018;12(1):47-54. https://doi.org/10.14412/1996-7012-2018-1-47-54
For citation:
Belov B.S., Bukhanova D.V., Tarasova G.M. Lower respiratory tract infections in rheumatic diseases. Modern Rheumatology Journal. 2018;12(1):47-54. (In Russ.) https://doi.org/10.14412/1996-7012-2018-1-47-54
Просмотров: 759
Послать статью по эл. почте 